Sermorelin (GHRH 1-29 NH₂) is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It is a selective agonist of the GHRH receptor (GHRHR) on pituitary somatotroph cells. Receptor activation stimulates pulsatile GH secretion via a cAMP/PKA signaling cascade, closely mimicking the natural hypothalamic GHRH pulse.

What is Sermorelin? GHRH 1-29 Analogue, GH Axis & Pulsatile GH Research

Q: How does Sermorelin differ from CJC-1295?

Both target the GHRH receptor, but have very different half-lives. Sermorelin (~10-20 min) closely mirrors native GHRH pulse kinetics and is used when physiological GH pulsatility needs to be preserved. CJC-1295 without DAC has ~30 min half-life; CJC-1295 with DAC extends to 6-8 days via albumin binding, producing sustained GHRHR occupancy and a blunted, tonic GH secretion pattern instead of discrete pulses.

Q: Is Sermorelin the same as Ipamorelin?

No. Sermorelin is a GHRH receptor (GHRHR) agonist. Ipamorelin is a growth hormone releasing peptide (GHRP) that targets the ghrelin receptor (GHSR-1a). They activate GH secretion through distinct receptors and second-messenger systems. They are complementary tools for studying GH axis biology, not alternatives for the same experiment.

Q: How do I reconstitute Sermorelin?

Reconstitute the 5mg vial with 2.5 mL Bacteriostatic Water for a concentration of 2 mg/mL. Inject slowly along the vial wall, swirl gently. Solution should be clear and colorless. Refrigerate at 2-8°C after reconstitution. Stable 28-42 days.

Overview

What is Sermorelin?

Sermorelin (formally designated GHRH 1-29 NH₂, or Sermorelin acetate) is a synthetic 29-amino acid peptide corresponding to the N-terminal fragment of endogenous growth hormone-releasing hormone (GHRH). Endogenous GHRH is a 44-amino acid hypothalamic peptide — Sermorelin retains positions 1–29, which constitute the receptor-binding domain responsible for all of GHRH's physiological activity. Residues 30–44 contribute to structural stability but not receptor binding.

Sermorelin was the first GHRH analogue approved for clinical use and remains a standard GH-axis research tool. It acts as a selective agonist of the GHRH receptor (GHRHR), a class B G-protein coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Activation of GHRHR stimulates pulsatile growth hormone secretion in a manner that closely mirrors the natural hypothalamic GHRH pulse — a fidelity to native physiology that distinguishes it from longer-acting GHRH analogues.

Property	Value
Full name	GHRH (1-29) NH₂ · Sermorelin acetate
Length	29 amino acids (N-terminal fragment of 44-AA endogenous GHRH)
Molecular weight	~3,357 Da
Receptor target	GHRH receptor (GHRHR) — Gs-coupled, class B GPCR
Half-life	~10–20 minutes (subcutaneous)
GH secretion pattern	Pulsatile (matches native GHRH physiology)
Primary research area	GH axis biology, somatotroph function, GH pulse studies
Reconstitution	2.5 mL BAC Water per 5mg → 2 mg/mL

Background

The GH Axis: Where Sermorelin Fits

The growth hormone axis is a multi-level neuroendocrine cascade that regulates GH secretion and its downstream anabolic and metabolic effects. Understanding the axis clarifies Sermorelin's mechanism and how it differs from other GH-related research compounds.

At the top of the axis, the hypothalamus generates two opposing hormones: GHRH (stimulatory) and somatostatin (inhibitory). These are secreted in pulses — GHRH drives GH release, somatostatin suppresses it. The net balance produces the characteristic pulsatile GH secretion pattern: brief bursts of GH release (predominantly during sleep and exercise) separated by low-GH baseline periods.

GHRH binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating a Gs → adenylyl cyclase → cAMP → PKA cascade that stimulates GH transcription and secretion. GH then enters circulation and acts on peripheral tissues — most importantly the liver, where it stimulates IGF-1 production. IGF-1 feeds back to suppress both hypothalamic GHRH and pituitary GH release, completing the negative feedback loop.

Sermorelin mimics the GHRH stimulus at the GHRHR, the first step of this cascade. Because Sermorelin's half-life (~10–20 min) closely matches native GHRH pulse duration, the GH response it produces is a discrete, time-limited pulse — physiologically faithful in a way that longer-acting analogues are not.

The GH Axis — Signal Flow

Hypothalamus: GHRH pulse (stimulatory) + Somatostatin (inhibitory) → Pituitary somatotrophs: GHRHR activation → cAMP/PKA → GH secretion → Circulation: GH acts on liver + muscle + adipose → Liver: IGF-1 production → Feedback: IGF-1 + GH suppress hypothalamic GHRH and pituitary GH

Sermorelin enters at the GHRHR step, producing a physiologically patterned pulse. CJC-1295 with DAC enters at the same step but produces tonic occupancy — a fundamentally different secretion profile.

Mechanism of Action

How Sermorelin Works

Sermorelin binds the GHRH receptor on somatotroph cells. The GHRHR is a class B GPCR (the same family as glucagon and GLP-1 receptors) that couples to Gs, the stimulatory G-protein. Gs activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which then:

Phosphorylates transcription factors that increase GH gene transcription
Promotes release of pre-formed GH vesicles via exocytosis (acute GH secretion)
Stimulates somatotroph proliferation and differentiation in longer-term models

The result is a pulse of GH release that mirrors the duration and amplitude of a natural hypothalamic GHRH stimulus. Because Sermorelin's half-life (~10–20 min) is close to native GHRH, the GHRHR occupancy terminates naturally, the somatotroph recovers to baseline, and normal somatostatin-mediated GH suppression can resume — preserving the ultradian rhythm of GH secretion.

This is in sharp contrast to CJC-1295 with DAC (~6–8 day half-life via albumin binding), which maintains continuous GHRHR occupancy and produces sustained, tonic GH elevation rather than discrete pulses. The physiological importance of GH pulsatility — pulse frequency and amplitude both affect tissue responses — is a key reason Sermorelin is often preferred over long-acting analogues in research requiring faithful GH axis physiology.

Comparison

Sermorelin vs CJC-1295 vs Ipamorelin

The GH axis research landscape involves three distinct compound classes: GHRH receptor agonists (Sermorelin, CJC-1295, Tesamorelin), GHRPs/ghrelin receptor agonists (Ipamorelin, GHRP-6, GHRP-2), and somatostatin inhibitors. Understanding the first two classes is essential for placing Sermorelin correctly.

Feature	Sermorelin	CJC-1295 (no DAC)	CJC-1295 (with DAC)	Ipamorelin
Receptor target	GHRHR	GHRHR	GHRHR	GHSR-1a (ghrelin receptor)
Class	GHRH analogue	GHRH analogue	GHRH analogue	GHRP (ghrelin mimetic)
Half-life	~10–20 min	~30 min	~6–8 days	~2 hours
GH secretion pattern	Discrete pulse (mimics native GHRH)	Discrete pulse (slightly prolonged)	Tonic/sustained elevation	Pulse (via separate pathway)
Signaling cascade	Gs → cAMP → PKA	Gs → cAMP → PKA	Gs → cAMP → PKA (sustained)	Gq/11 → IP₃/DAG → PKC (primarily)
Somatostatin interaction	Normal somatostatin suppression intact	Normal	Partial override of somatostatin	Reduces somatostatin tone
Best research use case	Native GHRH kinetics, pulse physiology	Extended pulse models	Chronic GH elevation studies	GHRP pathway, convergent activation
J.Pharma product	Sermorelin 5mg	CJC-1295 + Ipamorelin		CJC-1295 + Ipamorelin

GHRHR vs GHSR-1a — Two Different Pathways

Sermorelin and Ipamorelin both stimulate GH release from somatotrophs but through different receptors and different intracellular cascades. GHRHR activates Gs → cAMP → PKA. GHSR-1a (ghrelin receptor) activates Gq/11 → phospholipase C → IP₃/DAG → PKC. These converge on GH vesicle exocytosis but through distinct molecular intermediaries. Research using both simultaneously studies convergent activation — the combined effect is generally greater than either alone, which is why combination protocols (GHRH analogue + GHRP) are a standard GH axis research design.

Research Context

Research Applications

GH Pulse Physiology

Sermorelin's close mimicry of native GHRH kinetics makes it the compound of choice when research requires studying GH pulse dynamics — amplitude, frequency, duration, and the response of downstream IGF-1 to pulsatile vs tonic GH patterns. The pulsatile nature of GH secretion matters: pulse frequency determines receptor desensitization patterns, and pulse amplitude determines the magnitude of anabolic signaling in target tissues.

Somatotroph Biology

As a selective GHRHR agonist, Sermorelin is used to probe somatotroph cell biology — GHRHR expression levels, cAMP signaling dynamics, GH gene transcription regulation, and somatotroph proliferation/differentiation models. Sermorelin's discrete pulse profile makes it easier to study receptor kinetics than long-acting analogues that maintain continuous receptor occupancy.

GH Axis Deficiency Models

Sermorelin has been used in research investigating reduced GH axis activity in aging models, where hypothalamic GHRH output declines with age. Studies have explored whether restoring GHRH receptor stimulation can normalize GH pulse dynamics and downstream IGF-1 production in aged animals — a distinct research question from simply elevating GH via direct administration.

GHRHR vs GHSR-1a Pathway Dissection

Using Sermorelin alongside Ipamorelin in controlled designs allows researchers to isolate the contributions of each GH-releasing pathway to somatotroph response, IGF-1 output, and tissue-level effects. This pathway-dissection approach is valuable for understanding GH axis pharmacology and identifying which receptor pathway drives specific research endpoints.

Reconstitution

Reconstitution Protocol

Sermorelin 5mg ships as lyophilized powder. Reconstitute with 2.5 mL Bacteriostatic Water for a concentration of 2 mg/mL. Inject BAC water slowly along the vial wall — do not direct the stream onto the peptide powder or shake. Swirl gently until fully dissolved. Solution should be clear and colorless. Refrigerate at 2–8°C after reconstitution. Stable for 28–42 days.

Reconstitution Summary

Sermorelin 5mg: Add 2.5 mL BAC Water → 2 mg/mL. Inject along vial wall, swirl gently. Clear/colorless. Refrigerate 2–8°C. Stable 28–42 days.

Reconstitution Guide · Dosing Calculator · How to Reconstitute Peptides

FAQ

Common Questions

What is Sermorelin?

Sermorelin (GHRH 1-29 NH₂) is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It is a selective agonist of the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile GH secretion via a cAMP/PKA signaling cascade that closely mirrors the natural hypothalamic GHRH pulse.

How does Sermorelin differ from CJC-1295?

Both target the GHRH receptor, but their half-lives differ dramatically. Sermorelin (~10–20 min) closely mimics native GHRH pulse kinetics, producing discrete GH pulses and preserving normal GH pulsatility. CJC-1295 without DAC has ~30 min half-life; with DAC it extends to ~6–8 days, producing sustained GHRHR occupancy and a fundamentally different, tonic GH elevation pattern.

Is Sermorelin the same as Ipamorelin?

No. Sermorelin targets the GHRH receptor (GHRHR) via Gs/cAMP/PKA signaling. Ipamorelin targets the ghrelin receptor (GHSR-1a) via Gq/PKC signaling. They activate GH secretion through distinct receptors and cascades and are complementary research tools — often used together to study convergent GH-axis stimulation.

What is the GH axis and where does Sermorelin fit?

The GH axis runs: hypothalamus → pituitary → peripheral tissues. The hypothalamus secretes GHRH (stimulatory) and somatostatin (inhibitory) to regulate GH from pituitary somatotrophs. GH then stimulates IGF-1 in the liver, which feeds back to suppress GHRH and GH. Sermorelin mimics the GHRH stimulus at the GHRHR, the first step in this cascade.

How do I reconstitute Sermorelin?

Add 2.5 mL Bacteriostatic Water to the 5mg vial (2 mg/mL). Inject slowly along the vial wall, swirl gently. Clear and colorless solution. Refrigerate at 2–8°C. Stable 28–42 days.

📚 Related Research Guides

What is CJC-1295 + Ipamorelin? — long-acting GHRH analogue + GHRP combination · What is Tesamorelin? — GHRH analogue with DAC-free extended half-life · Ipamorelin vs CJC-1295 — GHRP vs GHRH pathway comparison · What is IGF-1 LR3? — downstream GH axis effector · All Research Guides →